全文获取类型
收费全文 | 1694篇 |
免费 | 72篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 73篇 |
妇产科学 | 9篇 |
基础医学 | 174篇 |
口腔科学 | 24篇 |
临床医学 | 235篇 |
内科学 | 313篇 |
皮肤病学 | 410篇 |
神经病学 | 27篇 |
特种医学 | 302篇 |
外科学 | 70篇 |
综合类 | 27篇 |
预防医学 | 30篇 |
眼科学 | 11篇 |
药学 | 77篇 |
肿瘤学 | 64篇 |
出版年
2022年 | 6篇 |
2021年 | 9篇 |
2020年 | 3篇 |
2019年 | 15篇 |
2018年 | 17篇 |
2017年 | 13篇 |
2016年 | 19篇 |
2015年 | 30篇 |
2014年 | 22篇 |
2013年 | 41篇 |
2012年 | 31篇 |
2011年 | 48篇 |
2010年 | 67篇 |
2009年 | 59篇 |
2008年 | 38篇 |
2007年 | 76篇 |
2006年 | 35篇 |
2005年 | 47篇 |
2004年 | 32篇 |
2003年 | 34篇 |
2002年 | 35篇 |
2001年 | 28篇 |
2000年 | 31篇 |
1999年 | 35篇 |
1998年 | 96篇 |
1997年 | 95篇 |
1996年 | 117篇 |
1995年 | 88篇 |
1994年 | 91篇 |
1993年 | 74篇 |
1992年 | 37篇 |
1991年 | 47篇 |
1990年 | 34篇 |
1989年 | 38篇 |
1988年 | 44篇 |
1987年 | 38篇 |
1986年 | 46篇 |
1985年 | 45篇 |
1984年 | 15篇 |
1983年 | 25篇 |
1982年 | 22篇 |
1981年 | 23篇 |
1980年 | 24篇 |
1979年 | 12篇 |
1978年 | 19篇 |
1977年 | 19篇 |
1976年 | 13篇 |
1975年 | 8篇 |
1969年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有1847条查询结果,搜索用时 0 毫秒
1.
2.
J.-P. Ortonne A. Taïeb A.D. Ormerod† D. Robertson‡ J. Foehl‡ R. Pedersen‡ C. Molta‡ B. Freundlich‡ 《The British journal of dermatology》2009,161(5):1190-1195
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
3.
4.
5.
6.
7.
8.
Pernes JM; Vitoux JF; Brenoit P; Raynaud A; Parola JL; Roth JP; Angel CY; Fiessinger JN; Roncato M; Gaux JC 《Radiology》1986,158(2):481-485
Thirty-five patients hospitalized for recent angiographically documented arterial occlusion in the legs (27 femoropopliteal arteries and eight grafts) benefited from local fibrinolytic therapy delivered at the site of the occlusion with a 4- or 5-F catheter. This therapy combined a continuous urokinase (UK) infusion of 1,000 U/kg/hour and a lysyl plasminogen (LYS-PLG) infusion of 15 microkatals every 30 minutes. Angiographically confirmed lysis was obtained in 85% of the cases. Only 3% of the patients had major and 6% had minor groin hematomas. Only two patients had concentrations of fibrinogen as low as 100 mg/dl. Intravascular infusion of UK-LYS-PLG is as effective as streptokinase. Its excellent tolerance makes it a good alternative in the treatment of acute ischemia in the lower limbs. 相似文献
9.
10.